earnings
confidence high
sentiment neutral
materiality 0.75
Krystal Biotech Q2 net loss widens to $28.1M; BLA filed for B-VEC, KB407 IND accepted
Krystal Biotech, Inc.
2022-Q2 EPS reported
-$3.08
- Q2 net loss $28.1M ($1.10/share) vs $16.4M loss YoY; cash $438.5M.
- Filed BLA for B-VEC (DEB therapy) with FDA on June 22, 2022.
- FDA accepted IND for KB407 (cystic fibrosis); Phase 1 trials expected 2H 2022.
- R&D expense $10.9M, G&A $17.9M; losses reflect increased commercial prep.
- Pipeline: KB105 dosing to resume 2H 2022; KB104 IND later 2022; KB301 Phase 2 in Q4 2022/Q1 2023.